학술논문
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
Document Type
Article
Author
Source
In Kidney International December 2023 104(6):1219-1226
Subject
Language
ISSN
0085-2538